Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020
Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces its unaudited interim results for the half year to 30 June 2020. Business Highlights for H1 2020 Continued to advance both wholly owned product … Continue reading Silence Therapeutics Reports Interim Results for the Six Months Ended 30 June 2020 Continue Reading
FOMO CORP.– Under an LOI to merge with FOMO this Fall, Purge Virus LLC (PV) is pleased to provide an update on the most recent developments with its Personal Protection Equipment (PPE) strategic partner, PPE Source International, LLC (PPESI). For examples of PPE inventory in U.S. warehouses with products and pricing, see: https://purgevirus.com/ppe/. PPE is increasingly in demand as … 
Euro Sun Mining Inc. is pleased to provide a corporate update and comment on the current strategy regarding development of the ten million gold equivalent ounce Rovina Valley Project. In response to many questions from shareholders, we would like to provide an update on recent developments at the Rovina Valley Project so that all investors have … 
African Gold Group, Inc. is pleased to announce that a 10,000 meter drill program has commenced at the Company`s flagship Kobada Gold Project in Southern Mali. The phase 3 program is designed to both increase resources through strike length extension drilling and upgrade certain inferred resources to indicated. The Company continues to focus on advancing the … 
NGMEX, a full-service commodity and multi asset exchange that incorporates the complete workflow of a trading venue and also provides on-line commodity futures and option trading, is pleased to announce that it has won three awards in the annual edition of the International Rankings for Outstanding Corporate Governance in Asia Pacific: Best Ranked Corporate Governance … 
Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 10,000,000 common shares (the “Common Shares”) of the Company (the “Offering”). The Common Shares are being sold at a public offering price of US$13.00 per Common … 
Itafos announced that it has commenced technical studies related to Itafos Conda organic growth projects, including anhydrous hydrogen fluoride and precipitated silica (“AHF/PS”) by-product recovery and on-site ammonia production, as part of the Company’s strategic focus on optimizing Itafos Conda’s EBITDA generation capability. The Company expects to provide a further update on the respective technical …